Literature DB >> 19274699

First preliminary results of an observation of Ginkgo Biloba treating patients with autistic disorder.

Helmut Niederhofer.   

Abstract

Deficits in reciprocal social interaction, verbal and nonverbal communication, and imaginative activity are the main characteristics of autism. From the psychopharmacological point of view, clonidine, metylphenidate and neuroleptics may improve some of these aspects, but with a remarkable risk of adverse side effects. In our observational study, three patients received 2 x 100 mg Ginkgo Biloba EGb 761 for 4 weeks and showed some improvement on the Aberrant Behavior and Symptom Checklist. These results suggest, that Ginkgo Biloba might be effective at least as an add-on therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19274699     DOI: 10.1002/ptr.2778

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  4 in total

1.  A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders.

Authors:  Elmira Hasanzadeh; Mohammad-Reza Mohammadi; Ahmad Ghanizadeh; Shams-Ali Rezazadeh; Mina Tabrizi; Farzin Rezaei; Shahin Akhondzadeh
Journal:  Child Psychiatry Hum Dev       Date:  2012-10

Review 2.  Neuroprotective Effects of Quercetin in Pediatric Neurological Diseases.

Authors:  Lourdes Alvarez-Arellano; Marcela Salazar-García; Juan Carlos Corona
Journal:  Molecules       Date:  2020-11-28       Impact factor: 4.411

Review 3.  Natural Antioxidants: A Novel Therapeutic Approach to Autism Spectrum Disorders?

Authors:  Luca Pangrazzi; Luigi Balasco; Yuri Bozzi
Journal:  Antioxidants (Basel)       Date:  2020-11-26

4.  Paving Plant-Food-Derived Bioactives as Effective Therapeutic Agents in Autism Spectrum Disorder.

Authors:  Natália Cruz-Martins; Cristina Quispe; Celale Kırkın; Ezgi Şenol; Aslı Zuluğ; Beraat Özçelik; Adedayo O Ademiluyi; Olubukola Helen Oyeniran; Prabhakar Semwal; Manoj Kumar; Farukh Sharopov; Victor López; Francisco Les; Iulia-Cristina Bagiu; Monica Butnariu; Javad Sharifi-Rad; Mohammed M Alshehri; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-08-21       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.